SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Trading update

12 Jan 2022 07:00

RNS Number : 1353Y
Frontier IP Group plc
12 January 2022
 

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

RNS

AIM: FIPP

12 January 2022

 

 

 

Frontier IP Group plc

("Frontier IP" or the "Group")

 

Trading update

 

Frontier IP (AIM: FIPP), a specialist in commercialising intellectual property, is today providing a trading update ahead of publication of its interim results for the six months to 31 December 2021 ("H1 2022") which are expected to be released in March 2022. The Group has enjoyed a strong first half to the financial year in particular due to the IPO on the Nasdaq Global Select Market of portfolio company Exscientia plc ("Exscientia") during the period.

 

Exscientia reported a strong set of quarterly results post admission and, on 7 January 2022, announced a strategic research collaboration with Sanofi that will entitle Exscientia to an upfront cash payment of $100 million with the potential for $5.2 billion in total milestones plus tiered royalties. The uplift in book value of this holding as at 31 December 2021 is expected to make a significant contribution to the performance of the Group in H1 2022.

Further to the release of the Group's full year results in October 2021, Frontier IP has now commenced a programme to realise part of its shareholding in Exscientia. As at the date of this announcement a small portion has been sold in January 2022 and the Group will provide a further update at the appropriate time.

The Group's portfolio as a whole has continued to show strong commercial and technical progress and a number of the companies are reaching key inflection points. During the period The Vaccine Group announced encouraging data on the development of its next generation COVID-19 vaccine, Camgraphic completed a fundraising and management was strengthened at Pulsiv. This momentum is continuing into 2022 and yesterday we were pleased to note Celerum launching its Truck Logistics System at a time when supply chain challenges are high on the priority list for many businesses.

 

While it is clear there are many challenges facing markets and industry, we anticipate reporting a set of results for H1 2022 ahead of management expectations and continuing to build on progress in the balance of the financial year. We remain confident on the Group's prospects for the remainder of the financial year and beyond.

 

ENQUIRIES

 

Frontier IP Group Plc

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

 

T: 020 3968 7815 neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

T: 0203 328 5656

Singer Capital Markets (Broker)

Sandy Fraser / Harry Gooden / George Tzimas

T: 0207 496 3000

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUAORRURUAAUR
Date   Source Headline
18th Feb 20257:00 amRNS-RTopps Tiles launches Alusid’s Mas floor tiles
31st Dec 20241:30 pmRNSTotal Voting Rights
30th Dec 20249:56 amRNSHolding(s) in Company
20th Dec 20247:00 amRNSGrant of Options
19th Dec 20244:14 pmRNSResult of AGM
29th Nov 20245:00 pmRNSTotal Voting Rights
29th Nov 20241:36 pmRNSHolding(s) in Company
27th Nov 20247:00 amRNSPosting of Circular & Annual Report, & AGM Notice
26th Nov 20247:00 amRNSResult of Retail Offer
22nd Nov 20241:31 pmRNSResult of Placing and Subscription
22nd Nov 20248:12 amRNSRetail Offer by PrimaryBid
22nd Nov 20247:01 amRNSProposed Placing and Subscription
22nd Nov 20247:00 amRNSFinal results for the year ended 30 June 2024
29th Oct 20244:45 pmRNSHolding(s) in Company
11th Sep 202412:10 pmRNSHolding(s) in Company
7th Aug 20243:52 pmRNSHolding(s) in Company
6th Aug 20243:47 pmRNSHolding(s) in Company
28th Jun 20247:00 amRNSPortfolio – Cambridge Raman Imaging loan facility
19th Jun 20247:00 amRNSHolding(s) in Company
24th May 20247:00 amRNSTopps Group’s arm launches Alusid floor tile range
7th May 202410:15 amRNSTVG to collaborate with The Pirbright Institute
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.